How can companies successfully engage with stakeholders to support better access to treatment for patients? In this Pharmaceutical Executive article, Andrew Butcher and Brian Kennedy, Executive Director of Alliance for Patient Access, outline six steps that help maximize the prospects for success in light of the evolving dynamics in stakeholder relationships.
Click here to read the article.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.